Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 6th SCS Healthcare Conference in Suzhou on September 2 to deliver a keynote speech. (IMAGE)

InSilico Medicine

Dr. Feng Ren, Co-CEO and CSO of Insilico Medicine, will attend the 6th SCS Healthcare Conference in Suzhou on September 2 to deliver a keynote speech.

Caption

As a leader in AI drug discovery, he will articulate how AI drives paradigm shifts in drug discovery, accelerating the transition from target identification to preclinical candidate nomination. He will also discuss leveraging core technologies to break R&D bottlenecks, enhance pipeline commercial value, and explore future opportunities with industry and capital market partners.

Credit

Insilico Medicine

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.